全球脉络膜视网膜炎治疗市场 – 行业趋势和 2029 年预测

全球脉络膜视网膜炎治疗市场分析和规模

近年来，脉络膜视网膜炎的发病率急剧上升。脉络膜视网膜炎是一种影响眼后部的葡萄膜炎。治疗葡萄膜和周围组织炎症的各种治疗方法被称为葡萄膜炎治疗。视力模糊、视野中出现暗斑或漂浮斑块、眼睛发红和对光敏感都是这种疾病的症状。如今，由于不健康的生活方式，各种自身免疫性疾病和慢性疾病的患病率不断上升，这也会增加脉络膜视网膜炎的风险。因此，导致市场上出现了脉络膜视网膜炎治疗药物。

• Data Bridge Market Research 分析称，2021 年脉络膜视网膜炎治疗市场价值为 5.11 亿美元，预计到 2029 年将达到 7.9922 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 5.75%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

全球脉络膜视网膜炎治疗市场定义

脉络膜视网膜炎是脉络膜（视网膜内膜）的炎症。这种炎症会导致视力问题。治疗的目的是保持患者的视力完好无损。如果存在感染，治疗的重点是根除感染并抑制宿主的炎症反应。在感染情况下，抗炎药物在开始使用抗感染药物后 48 至 72 小时内给药。皮质类固醇和免疫抑制药物是非感染性后葡萄膜炎最常见的治疗方法。

脉络膜视网膜炎治疗市场动态

驱动程序

• 慢性病、传染病发病率高

艾滋病毒/艾滋病、结核病、梅毒、先天性风疹等慢性传染病的发病率上升将成为市场增长率扩大的主要驱动力。与此同时，结节病、结节性多动脉炎和类风湿性关节炎等自身免疫性疾病病例的增加将在预测期内推动市场增长率。

• 增加医疗基础设施投资

影响脉络膜视网膜炎治疗市场增长率的另一个重要因素是医疗保健支出的增加，这有助于改善其基础设施。

此外，公共和私人组织不断提高认识的举措以及老年人口的增加是扩大脉络膜视网膜炎治疗市场的因素。生活方式的不断变化和可支配收入水平的提高等其他因素将对脉络膜视网膜炎治疗市场的增长率产生积极影响。此外，政府实施的促进健康的有利举措将导致脉络膜视网膜炎治疗市场的扩大。 

机会

• 脉络膜视网膜炎治疗的投资和研究资金的增加将促进增长率

此外，研发活动的投资和资金水平的上升将为市场增长率带来新的机遇。

此外，与各种公共和私人组织的战略合作伙伴关系数量的激增以及医疗技术的进步将为 2022-2029 年预测期内的脉络膜视网膜炎治疗市场提供有利机会。

全球脉络膜视网膜炎治疗市场的限制/挑战

然而，治疗费用高昂以及低收入国家基础设施缺乏将阻碍脉络膜视网膜炎治疗市场的增长率。此外，与脉络膜视网膜炎及其治疗相关的并发症将阻碍脉络膜视网膜炎治疗市场的增长。由于 COVID-19 疫情爆发而出现的不利条件以及患者意识的降低将在上述预测期内进一步挑战市场。

本脉络膜视网膜炎治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关脉络膜视网膜炎治疗市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

患者流行病学分析

根据多项研究的流行病学数据，在美国，每年每 100,000 人中就有 52 至 341 人患有葡萄膜炎。在美国，它导致 2.8% 至 10% 的失明病例。全球最常见的后葡萄膜炎病因是弓形虫脉络膜视网膜炎。炎热潮湿的热带国家发病率更高。在美国，它占所有后葡萄膜炎病例的 25%。大约 20% 的美国成年人体内有弓形虫抗体。研究表明，随着年龄的增长，葡萄膜炎变得越来越常见。它每年导致美国约 30,000 例新发失明病例，占全国所有失明病例的 10% 至 15% 左右。女性比男性更容易患上眼部炎症性疾病，并且大多数患者处于育龄阶段。

脉络膜视网膜炎治疗市场还为您提供详细的市场分析，以进行患者分析、预后和治疗。患病率、发病率、死亡率、依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健、更全面的多元统计模型，用于预测增长期的市场。

COVID-19 对脉络膜视网膜炎治疗市场的影响

自 2019 年 12 月出现以来，COVID-19 病毒已传播到地球上几乎每个国家，促使世界卫生组织 (WHO) 宣布其为公共卫生紧急事件。由于金融危机和在优先考虑 COVID-19 相关治疗的同时专业医疗服务延迟，世界各地的医疗保健系统在冠状病毒大流行后受到严重破坏。患者无法看到他们的控制，原因多种多样，包括难以找到医生、害怕感染传播、由于大流行限制而无法继续治疗和基本程序。这些考虑可能会对近几个月的脉络膜视网膜炎治疗市场产生负面影响。

全球脉络膜视网膜炎治疗市场范围

脉络膜视网膜炎治疗市场根据治疗、诊断、症状、剂量、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

治疗

• 药物
• 外科手术
• 其他的

根据治疗方法，脉络膜视网膜炎治疗市场分为药物治疗、手术治疗和其他治疗。药物治疗细分为皮质类固醇、免疫抑制剂、抗炎剂、抗感染剂和其他治疗。手术细分为玻璃体切除术、激光光凝术和冷冻疗法。

诊断

• 血液检查
• 体格检查
• 其他的

根据诊断，脉络膜视网膜炎治疗市场分为血液检查、体检和其他。

症状

• 眼睛疼痛或发红
• 火花的感觉
• 对光敏感
• 夜视能力受损
• 过度撕裂
• 色觉受损
• 视力模糊
• 物体扭曲
• 其他的

根据症状，脉络膜视网膜炎治疗市场分为眼睛疼痛或发红、火花感、对光敏感、夜视受损、流泪过多、色觉受损、视力模糊、物体扭曲等。

剂量

• 注射
• 平板电脑
• 眼药水
• 其他的

根据剂量，脉络膜视网膜炎治疗市场分为注射剂、片剂、眼药水和其他剂型。

给药途径

• 口服
• 肠外
• 主题
• 其他的

On the basis of route of administration, the chorioretinitis treatment market is segmented into oral, parenteral, topical and others.

End Use

• Clinic
• Hospital
• Others

On the basis of end-users, the chorioretinitis treatment market is segmented into clinic, hospital and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

The chorioretinitis treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Chorioretinitis Treatment Market Regional Analysis/Insights

The chorioretinitis treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the chorioretinitis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the chorioretinitis treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.

Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increasing patient pool, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Chorioretinitis Treatment Market Share Analysis

The chorioretinitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to chorioretinitis treatment market.

Some of the major players operating in the chorioretinitis treatment market are Novartis AG (Switzerland), AstraZeneca (UK), Merck & Co., Inc. (US), Sumitomo Corporation (Japan), Allergan (Ireland), LEO Pharma A/S (Denmark), Cipla Inc. (US), Eli Lilly and Company (US), Bayer AG (Germany), Abbott (US), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Johnson & Johnson Private Limited (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd. (Switzerland), and Mylan N.V. (US), among others.

Research Methodology : Global Chorioretinitis Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-chorioretinitis-treatment-market

SKU-67983